BioSpace News Archive

Takeda has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka.

Antengene Corporation Limited announced that South Korea’s National Health Insurance Service has approved the reimbursement of XPOVIO® for the treatment of adult patients with relapsed or refractory multiple myeloma.

ANEW MEDICAL, INC. announces that is has been granted and issued a patent in Europe, EP3377091B1, for the use of ANEW’s secreted Klotho gene sequence and gene delivery systems to be used in the treatment of diminished cognition, memory loss, dementia and other neurodegenerative diseases.

Medicenna Therapeutics Corp. today announced that the European Medicines Agency (“EMA”) has approved the Clinical Trial Application (“CTA”) for the conduct of the Phase 1/2 ABILITY-1 (A Beta-only IL-2 ImmunoTherapY) Study with MDNA11 either alone or in combination with pembrolizumab (KEYTRUDA®) thereby expanding the clinical trial in the European Union (“EU”).

VYNE Therapeutics Inc. today announced members of VYNE’s management will participate in one-on-one meetings at the Leerink Partners Therapeutics Forum on Immunology and Inflammation and Metabolic Diseases on Tuesday, July 9, 2024.

Oruka Therapeutics, Inc. today announced the appointment of Paul Quinlan, former General Counsel of CymaBay Therapeutics, as General Counsel & Secretary and Alan Lada, former Vice President of Equity Capital Markets at Guggenheim Partners, as Vice President of Investor Relations.

Oryzon Genomics, S.A. today announced that it will present final data from its Phase IIb PORTICO trial, which investigated the efficacy of vafidemstat in the treatment of Borderline Personality Disorder (BPD), as an oral presentation at the 37th European College of Neuropsychopharmacology (ECNP) annual conference, to be held on September 21-23, 2024 in Milan, Italy.

EyePoint Pharmaceuticals, Inc. today announced the Company will highlight clinical and regulatory developments for its lead pipeline program, DURAVYU™.

Solarea Bio, a pioneering biotechnology company focused on developing solutions to improve human health by harnessing the edible plant microbiome, announces the appointment of Ilissa Larimore as Chief Commercial Officer.

BrainStorm Cell Therapeutics Inc. ment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm’s Phase 3b clinical trial for NurOwn.